Background: Streptococcus pneumoniae is an important cause of morbidity and mortality in Southeast Asia, but regional data is limited. Updated burden estimates are critical as pneumococcal conjugate vaccine (PCV) is highly effective, but not yet included in the Expanded Program on Immunization of Thailand or neighboring countries.
Introduction
In 2009, The Hib and Pneumococcal Global Burden of Disease Study Team estimated that Streptococcus pneumoniae caused nearly 5.5 million meningitis, sepsis, and pneumonia cases and .185,000 deaths in Southeast Asia annually, but noted that regional prevention decisions, 'will need to be made on the basis of limited regional data' [1] . Similarly, The Asian Strategic Alliance for Pneumococcal Disease Prevention concluded that 'pneumococcal disease is an important cause of morbidity and mortality in the Asian region' and highlighted the 'urgent' need for 'more substantial studies' describing invasive pneumococcal disease burden in the Asia region [2] .
Although WHO recommends pneumococcal conjugate vaccine (PCV) vaccination even in the absence of local data, policymakers often require local data to weigh costs and benefits [3] . Besides a paucity of local data, policymakers in Southeast Asian countries are faced with weighing the potential benefits of PCV against those of several other effective vaccines, including those against rotavirus, influenza, and human papillomavirus. Currently, PCV is not included in the National Expanded Programs of Immunization of Thailand or neighboring countries, though PCV it is available on the private market in Thailand [4] .
Cost reductions are anticipated as the PCV Advanced Market Commitment is expected to increase demand, mass production, and manufacturer competition [5] . We aim to provide local and regional data to inform decision making as these changes occur. Previously, we published the first population-based estimates of pneumococcal bacteremia incidence in Southeast Asia [6] . The purpose of this report is to update these estimates and to contribute to an evidence base upon which sound policy decisions can be made. [6, 8] .
Methods

Setting
Patients
Physicians request blood cultures from hospitalized patients as clinically indicated. Limited data (age, province, and pre-blood culture antibiotic use) are available for patients who are in the bloodstream infection surveillance system only. Detailed clinical and demographic information is available for patients who were also captured in the IEIP pneumonia surveillance system.
Specimen Collection and Laboratory Methods
Blood cultures collected at district hospitals were transported at 15-30uC within 24 hours and processed at provincial hospital laboratories using the BactT/ALERTH 3D microbial detection system (bioMeriéux). Each blood specimen was divided between a bottle optimized for standard aerobic growth and a bottle for enhanced growth of fastidious pathogens, with priority given to inoculating at least 10 ml from adults and 4 ml from children ,5 years of age into the standard bottle. Bottles that signaled positive growth (alarm-positive) were subcultured using standard methods [9] .
Serotyping was performed using multiplex polymerase chain reaction (PCR) [10] . For isolates that could not be typed by this method, Quellung serotyping was done at the Streptococcus Reference Laboratory, U.S. Centers for Disease Control and Prevention in Atlanta, Georgia. Antimicrobial susceptibilities were determined by the disk-diffusion method with MIC values of penicillin and cefotaxime determined by Etest (AB Biodisk). Penicillin susceptibility interpretations used the 2008 Clinical and Laboratory Standards Institute guidelines for non-meningitis isolates: susceptible, #2 mg/ml; intermediate, 4 mg/ml; resistant $8 mg/ml [11] .
Antibiotic use before blood culture was determined by a serum disc assay. A filter paper disc coated with patient serum was placed onto a Mueller-Hinton agar plate inoculated with pan-sensitive Staphylococcus aureus (ATCC 9144) and growth inhibition was measured after 24 hours incubation at 35-37uC, [6, 12] .
Statistical Analysis
We calculated the observed (i.e., minimum) incidence of pneumococcal bacteremia requiring hospitalization using personyears of follow-up based on province specific annual population estimates from the National Economic and Social Development Board of Thailand [7] . Population estimates for infants were obtained by applying the proportion of children ,1 year old among all children ,5 years old nationally to the surveillance population aged ,5 years [13]. Exact 95% confidence intervals (CI) were calculated based on a Poisson distribution. Statistical analyses were done using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
From May 2005 through March 2010, 5,118 of 67,516 (7.6%) blood cultures performed in these 2 provinces were positive for any pathogen, S. pneumoniae was isolated from the blood of 196 patients: 92 from Sa Kaeo province and 104 from Nakhon Phanom. S. pneumoniae was isolated from 0.33% of 27,655 blood cultures in Sa Kaeo compared to 0.26% (104/39,855) in Nakhon Phanom.
Among all patients with blood cultures, 25% were less than 5 years old and 25% were 65 years and older (Table 1) . Deaths were more common among patients with pneumococcal bacteremia from Sa Kaeo: 37% (n = 34) in SK vs. 12% (n = 12) in NP. Additional clinical details were available for 130 of 196 patients with pneumococcal bacteremia who were also captured by IEIP's pneumonia surveillance system. Of these, 86% had respiratory symptoms, 100% had evidence of acute infection and 86% (111/ 130) had both, and thus met IEIP's criteria for clinical pneumonia. Pneumonia (ICD-10 codes J14-J19) was the discharge diagnosis for 45% (58/130) and septicemia (ICD-10 code A41.9) for another 22% (29/130). Case-patients from Sa Kaeo were more likely to receive oxygen or be intubated: oxygen use (77% in SK vs. 50% in NP, p = 0.001), intubation (46% in SK vs. 16% in NP, p,0.001), which is consistent with the higher case fatality rate observed in Sa Kaeo.
Antibiotic use before blood culture was common; 25.4% (11,123/43 ,720) of those tested had serum antimicrobial activity. Among pneumococcal bacteremia cases, serum antimicrobial activity was found in only 5 of the 135 tested (3.7%).
Hospitalized pneumococcal bacteremia incidence rates were highest among young children and older adults and varied by year (Figure 1 ). Overall incidence ranged from 2.3 per 100,000 personyears in 2006 to 4.1 in 2009 (data for 2005 and 2010 were incomplete and not considered). Among children less than 5 years old, the highest annual incidence rate was observed in 2007: 18.5 per 100,000. Among infants ,1 year old, the average annual incidence was 33.8 per 100,000 (95% CI 21.4, 50.7).
The median number of pneumococcal bacteremia cases per month was significantly higher during December through March compared to the rest of the year: 6.0 cases per month during December-March vs. 1.0 during April-November (p,0.001) (Figure 2) . This difference was observed in both Sa Kaeo and Nakhon Phanom provinces (data not shown).
Serotyping was completed for 191 (97%) of 196 isolates and 39 (98%) of 40 isolates from children ,5 years old. Serotypes 14 and 23F were most common among both children and adults; by contrast, serotype 3 was common among adults, but not found in children ,5 years.
Among children aged ,5 years, serotypes contained in the current 10-and 13-valent pneumococcal conjugate vaccines (PCV10 and PCV13) comprised 74%, and 92% of cases, respectively, exceeding the proportions among cases overall (Figure 3) . Antibiotic susceptibility testing was available for 193/196 isolates with the results as follows: co-trimoxazole non-susceptibil- ity was 57% (n = 109); erythromycin 30% (n = 57); clindamycin 21% (n = 40); chloramphenicol 12% (n = 23). All isolates were susceptible to penicillin and cefotaxime. Non-susceptibility to 3 or more of the above antibiotics was observed in 18% (35/193).
Isolates with serotypes included in PCV10 were more likely to be non-susceptible to co-trimoxazole, erythromycin, and clindamycin compared to non-PCV10 serotype isolates: 63% vs. 45% for cotrimoxazole; 42% vs. 10% for erythromycin; and 30% vs. 5.5% for clindamycin.
Discussion
Based on 196 S. pneumoniae isolates collected during 4.4 years of bloodstream infection surveillance in 2 rural provinces, we estimated the overall incidence of hospitalization for pneumococcal bacteremia in rural Thailand at 3.5 per 100,000 person-years. Rates were highest among children ,5 years old (11.1 per 100,000 person-years) and adults 65 years and older (13.6 per 100,000 person-years).
These findings demonstrate that S. pneumoniae is an important cause of severe disease requiring hospitalization in Thailand. However, these data certainly underestimate the true incidence of pneumococcal bacteremia. First, we only captured hospitalized cases, and data from the United States suggest that most pneumococcal bacteremia cases in young children occur among outpatients [14] . Second, despite increased use of blood cultures since implementation of automated blood culture processing in 2005, many patients who would likely have blood culture performed in higher resource settings do not receive them in rural Thailand. From May 2005 through June 2007, only 66% of patients with indications for blood culture had a culture performed and for patients ,5 years old the proportion was just 47% [6] . Furthermore, pre-culture antibiotic use remains common in this setting. We recently examined this issue and estimated that preculture antibiotics reduced our pneumococcal bacteremia inci- dence rates by 32% overall and 39% in children ,5 years of age [12] . Finally, our surveillance does not include other manifestations of invasive pneumococcal disease, such as meningitis, arthritis or osteomyelitis.
These incidence estimates are comparable to our previously reported estimates examining 72 S. pneumoniae isolates from 23,853 blood cultures performed from May 2005 through June 2007 [6] . However, our previous report included estimates based on a combination of cases identified via S. pneumoniae isolation and cases identified only by Binax NOWH immunochromatographic test (ICT) on broth of blood cultures that had a positive signal in the BactT/ALERTH machine but were negative on sub-culture (alarm positive, sub-culture negative). The current report does not include these ICT-only cases, because more recent investigations indicate false-positive tests can occur [15] and we are formally evaluating this unlicensed application of ICT. Alarm positive, sub-culture negative bottles continue to pose a dilemma in our laboratories; from January through March 2010, 89 (2.2%) of 3891 blood cultures were alarm positive, sub-culture negative.
The proportion of fatal cases in Nakhon Phanom province (12%) was comparable to that reported in other publications from Thailand: 8.2% from Siripongpreeda et. al. (all invasive pneumococcal disease), 16% from Netsawang et. al (non-meningitis), 13.3% (non-meningitis) in Suwanpakdee et al. [16] [17] [18] . By comparison, the case fatality rate in Sa Kaeo province (37%) seemed unusually high. Unfortunately, data detailing clinical characteristics, treatment, and underlying conditions were not available to investigate this unusually high case fatality rate. However, our data do suggest that severity of illness differed between the 2 provinces, with substantially more patients in Sa Kaeo requiring oxygen and intubation.
We documented consistent, statistically significant seasonal increases in pneumococcal bacteremia from December through March, which substantiates the seasonal increase noted in other reports from Thailand [16] , [17] , [19] , [20] . This seasonal pattern coincides, approximately, with Thailand's cool season (November through February) and the seasonal increases in pneumococcal disease observed in the U.S. and other temperate regions during the winter months [21, 22] . Interestingly, the pneumococcal bacteremia peaks in Thailand occurred during opposite times of year as Thailand's usual influenza season [23, 24] , which differs from temperate climates where invasive pneumococcal disease and influenza peaks coincide [25] . This report includes data during the 2009 influenza pandemic, which first peaked in Thailand from July to September 2009, during which time pneumococcal bacteremia rates were low (Figure 2) .
We observed that a high proportion of pneumococcal bacteremia cases among children aged ,5 years were caused by serotypes covered by PCV10, and that with the addition of PCV13 serotypes, coverage increases from 74% to 92% for children ,5 years old and from 61% to 82% overall. In a 2010 report, Thai researchers in the Bangkok area found that a similarly high proportion of IPD cases among children aged ,5 years were caused by vaccine serotypes: 70% and 81% for PCV7 and 13 respectively [26] . The Thailand National Institute of Health reported even higher proportions of vaccine serotypes among children aged ,5 years with invasive disease (80% for PCV10 and 92% for PCV13) [27] . Taken together these findings provide strong evidence that high coverage could be expected from PCV13 in Thailand.
All pneumococcal isolates were sensitive to penicillin, although we observed high rates of antibiotic non-susceptibility to a variety of other drugs, which is in agreement with many reports from Thailand [16, 18, 19, 28] and the region [29] . Our finding that antibiotic non-susceptibility is significantly higher among PCV serotypes corroborates other reports from Thailand and suggests that enactment of PCV implementation could help reduce antibiotic non-susceptibility, as was seen in the U.S. after vaccine introduction [30, 31] .
These findings document the ongoing burden of hospitalized pneumococcal bacteremia, which represents a small fraction of the total pneumococcal disease burden. In previous work among adults, we found that blood culture alone underestimates the incidence of hospitalized pneumococcal pneumonia cases by at least 9-fold [32] . Taken together with recent reports from other pneumococcal researchers in Thailand, our findings highlight the potential impact of PCV in Thailand and underscore the need for cost effectiveness data to inform vaccine policy discussions and decision making.
